Agenix Limited to File for China Clinical Trials of Hepatitis Treatment

Published: Apr 02, 2012

April 2, 2012 -- Agenix, an Australian biopharma, plans to file an application in Q3 with the SFDA to begin China clinical trials of its lead drug. AGX-1009 is a treatment for hepatitis B. Agenix bought the rights to the drug from the Institute of Medicinal Biotechnology at the Chinese Academy of Medical Sciences in 2010. The company expects the trials themselves will get underway in 2013. More details....

Stock Symbol: (ASX: AGX)

Back to news